Efficacy and safety of fast-acting insulin aspart versus insulin aspart both in combination with insulin degludec with or without metformin in adults with diabetes

被引：0
|
作者：
Du, J. [1 ]
Wang, G. X. [2 ]
Wang, G. [3 ]
Liu, M. [4 ]
Thamattoor, U. K. [5 ]
Luan, Z. J. [6 ]
Alibegovic, A. C. [7 ]
Mu, Y. M. [1 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[2] First Hosp Jilin Univ, Jilin, Jilin, Peoples R China
[3] Beijing Chao Yang Hosp, Beijing, Peoples R China
[4] Tianjin Med Univ Gen Hosp, Tianjin, Peoples R China
[5] Novo Nordisk India Private Ltd, Global Business Serv, Bangalore, Karnataka, India
[6] Novo Nordisk, Beijing, Peoples R China
[7] Novo Nordisk AS, Soborg, Denmark
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
739
引用
收藏
页码：S377 / S377
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of fast-acting insulin aspart compared with insulin aspart, both with insulin degludec with or without metformin, in adults with type 2 diabetes
    Lane, W.
    Bozkurt, K.
    Favaro, E.
    Jang, H. C.
    Kjaersgaard, M. I. S.
    Oviedo, A.
    Rose, L.
    Senior, P.
    Sesti, G.
    Soto Gonzalez, A.
    Franek, E.
    DIABETOLOGIA, 2019, 62 : S10 - S11
  • [2] A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)
    Lane, Wendy S.
    Favaro, Elena
    Rathor, Naveen
    Jang, Hak C.
    Kjaersgaard, Maiken I. S.
    Oviedo, Alejandra
    Rose, Ludger
    Senior, Peter
    Sesti, Giorgio
    Soto Gonzalez, Alfonso
    Franek, Edward
    DIABETES CARE, 2020, 43 (08) : 1710 - 1716
  • [3] Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial
    Bode, Bruce W.
    Iotova, Violeta
    Kovarenko, Margarita
    Laffel, Lori M.
    Rao, Paturi V.
    Deenadayalan, Srikanth
    Ekelund, Magnus
    Larsen, Steffen Falgreen
    Danne, Thomas
    DIABETES CARE, 2019, 42 (07) : 1255 - 1262
  • [4] Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial
    Komatsu, Mitsuhisa
    Ekelund, Magnus
    Horio, Hiroshi
    Kadowaki, Takashi
    ENDOCRINE JOURNAL, 2021, 68 (04) : 429 - 440
  • [5] Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan
    Kawamura, Tomoyuki
    Kikuchi, Toru
    Horio, Hiroshi
    Rathor, Naveen
    Ekelund, Magnus
    ENDOCRINE JOURNAL, 2021, 68 (04) : 409 - 420
  • [6] Efficacy and safety of fast-acting insulin aspart in adults with type 2 diabetes with different insulin requirements
    Sesti, G.
    Lane, W.
    Ekelund, M.
    Thorisdottir, O.
    Jodar, E.
    Oviedo, A.
    Rathor, N.
    Senior, P.
    Franek, E.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S330 - S330
  • [7] Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial
    Buse, John B.
    Carlson, Anders L.
    Komatsu, Mitsuhisa
    Mosenzon, Ofri
    Rose, Ludger
    Liang, Bo
    Buchholtz, Kristine
    Horio, Hiroshi
    Kadowaki, Takashi
    DIABETES OBESITY & METABOLISM, 2018, 20 (12): : 2885 - 2893
  • [8] ONSET 1: EFFICACY AND SAFETY OF MEALTIME FAST-ACTING INSULIN ASPART VERSUS INSULIN ASPART AFTER 52 WEEKS
    Bode, B.
    Mathieu, C.
    Franek, E.
    Philis-Tsimikas, A.
    Rose, L.
    Graungaard, T.
    Osterskov, A. B.
    Russell-Jones, D.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A29 - A29
  • [9] Efficacy and Safety of Faster Aspart Compared with Insulin Aspart Both with Insulin Degludec in Adults with T1D
    Buse, John B.
    Carlson, Anders
    Komatsu, Mitsuhisa
    Mosenzon, Ofri
    Rose, Ludger
    Liang, Bo
    Horio, Hiroshi
    Kadowaki, Takashi
    DIABETES, 2018, 67
  • [10] Efficacy and Safety of Fast-Acting Insulin Aspart Are Maintained over 52 Weeks: Comparison with Insulin Aspart in Onset 1
    Mathieu, Chantal
    Bode, Bruce W.
    Franek, Edward
    Philis-Tsimikas, Athena
    Rose, Ludger
    Graungaard, Tina
    Osterskov, Anne Birk
    Russell-Jones, David
    DIABETES, 2017, 66 : A258 - A258
12345